本報告已在2011年05月13日停止出版。
伴隨著肥胖人口比率的上昇與高齡化，在美國及歐洲的 2 型糖尿病病患數超過了 3,000 萬人，並且一般認為2012年將會突破 4,000 萬人次。
專門在各產業區塊裡，從事成長市場策略性調查的英國市調公司 Business Insight（總公司：倫敦），與專門提供醫藥品產業情報的 IMS Health (總公司：美國康迺迪克州)合作，調查與分析糖尿病治療市場，並有系統地出版綜合報告書 "The Diabetes Market Outlook: Market analysis of future growth and leading players by sector" 。
此報告書使用包括圖表在內的154頁篇幅，除了說明糖尿病治療藥的歷史、胰島素及OAD（口服糖尿病治療藥）市場的業績；分析企業的品牌佔有狀況、動向、發展促進因素；也探討主要企業的 OAD 市場的佔有狀況、提供製品與通路開發狀況等。此報告書的概略架構如下所示。
第1章 疾病學分析
- 摘要
- 前言
- 疾病說明
- 現在與未來的糖尿病罹患率
- 診斷
- 糖尿病治療藥的簡易清單
- 現在與未來治療模式
第2章 糖尿病治療的全球市場分析
- 摘要
- 前言
- 糖尿病治療藥的歷史
- 現在發展促進因素
- 未來發展促進因素
- 非注射胰島素藥劑
- Dual PPAR 吸入劑
- GLP-1 吸入劑與 DPP IV 抑制劑
- Amylinomimetic 藥劑
第3章 胰島素市場分析
- 摘要
- 前言
- 胰島素的種類與銷售
- 企業的市場佔有狀況
- 品牌佔有與銷售
- 人體胰島素
- 超速效型胰島素
- 持續型胰島素
第4章 OAD（口服糖尿病治療藥）市場分析
- 摘要
- 前言
- OAD 的種類與銷售
- 企業的市場佔有狀況
- Sulfonylurea（血糖下降劑）
- 雙胍胱類藥
- Sulfonylurea ＆ 雙胍胱類的組合藥
- TZD 藥
- AGI 藥
- 其他 OAD 藥
第5章 主要企業
- 摘要
- 前言
- Eli Lilly
- Novo Nordisk
- Sanofi-Aventis
- 武田藥品
- GlaxoSmithKline
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Merck KGaA
圖表
Business Insights have teamed up with IMS Health to bring you, The Diabetes Market Outlook: Market analysis of future growth and leading players by sector This unique product offering provides an analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data, an unrivalled source of pharmaceutical intelligence on the diabetes market.
This report analyzes diabetes market dynamics and provides a country-by-country drug and brand analysis enabling you to assess product success/failure within US and European geographical markets. This report focuses on the market segmentation of key anti-diabetic drugs (insulin and oral anti-diabetic (OAD)), and also reviews the growth strategies of leading players in the diabetics market. Upcoming revolutionary products in development are also investigated, highlighting those expected to drive market growth in the future and transform the treatment options for diabetic patients.
Diabetes type 2 has now reached epidemic levels, affecting over 30 million people in the US and Europe, with this figure projected to rise to over 40 million by 2012. Rising rates of obesity and the increasing age demographic are key drivers of this epidemic. Ensure you maximize the opportunities presented by this demographic growth, drive product development and exploit new and existing revenue streams in this rapidly growing market. Executive summary
- Epidemiology analysis
- Global diabetes market analysis
- Insulin market analysis
- Oral antidiabetic (OAD) market analysis
- Leading players in the diabetes market
Chapter 1 Epidemiology analysis
- Summary
- Introduction
- Disease description
- Type 1 diabetes
- Type 2 diabetes
- Current and future prevalence of diabetes
- Diagnosis
- Fast-track review for diabetes drugs
- Current and future treatment patterns
- Insulin prescribing
- TZD prescribing
Chapter 2 Global diabetes market analysis
- Summary
- Introduction
- History of antidiabetic drugs
- Current growth drivers
- Insulins
- TZDs
- Combination therapies
- Future growth drivers
- Non-injected insulin
- Inhaled insulins
- Oral insulins
- Insulin patches
- Dual PPAR agonists
- GLP-1 agonists and DPP IV inhibitors
- GLP-1 agonists
- DPP IV inhibitors
- Amylinomimetic agents
Chapter 3 Insulin market analysis
- Summary
- Introduction
- Insulin categories and sales
- Company market share
- Brand market share and sales
- Human Insulins
- Brand analysis
- Humulin (human insulin)
- NovoLin (human insulin)
- Fast-acting human insulin analogs
- Brand analysis
- Humalog (insulin lispro)
- NovoLog (insulin aspart)
- Apidra (insulin glulisine)
- Long-acting insulin analogs
- Brand analysis
- Lantus (insulin glargine)
- Levemir (insulin detemir)
Chapter 4 Oral antidiabetic (OAD) market
- analysis
- Summary
- Introduction
- OAD categories and sales
- Company market share
- Sulfonylurea products
- Brand market share and sales
- Brand analysis
- Amaryl (glimepriride)
- Glucotrol XL (glipizide)
- Biguanide products
- Brand market share and sales
- Brand analysis
- Glucophage & Glucophage XR (metformin)
- Combined sulfonylurea & biguanide products (and other combination
- therapies)
- Sulfonylurea + biguanide single-pill combination drugs
- Glucovance (glyburide + metformin)
- TZD + other OAD single-pill combination therapies
- Thiazolidinedione (TZD) products
- Brand market share and sales
- Brand analysis
- Drug analysis
- Actos (pioglitazone)
- Avandia (rosiglitazone)
- Avandamet (rosiglitazone + metformin)
- Alpha glucosidase inhibitor (AGI) products
- Brand market share and sales
- Brand analysis
- Precose/Glucobay (acarbose)
- Basen (voglibose)
- Glyset/Diastabol (miglitol)
- Other OAD products (the prandial glucose regulators)
- Brand market shares and sales
- Brand analysis
- Prandin/NovoNorm (repaglinide)
- Starlix (nateglinide)
Chapter 5 Leading players in the diabetes
- market
- Summary
- Introduction
- Eli Lilly
- Therapeutic focus
- Insulin market share
- Marketed products
- R&D pipeline
- Exenatide (synthetic exendin-4)
- Ruboxistaurin
- Pulmonary insulin (AIR)
- Oralin
- LY-818 (naveglitazar)
- Novo Nordisk
- Therapeutic focus
- Insulin market share
- Marketed products
- R&D pipeline
- NovoMix 50 and 70 (NN1185): Injectable insulin formulations
- AERx iDMS (NN1998): An inhaled insulin
- Liraglutide (NN2211)
- Sanofi-Aventis
- Therapeutic focus
- Insulin and OAD market shares
- R&D pipeline
- Exubera
- DiaPep277
- Takeda
- Therapeutic focus
- OAD market share
- Marketed products
- R&D pipeline
- Actos/metformin combination
- ATL-962
- TAK-559
- TAK-654
- TAK-428
- GlaxoSmithKline
- Therapeutic focus
- OAD market share
- Marketed products
- R&D pipeline
- Avandaryl
- Avandamet XR
- HIM-2
- 677954
- Bristol-Myers Squibb
- Therapeutic focus
- OAD market share
- Marketed products
- R&D pipeline
- Muraglitazar
- Basulin
- Inhaled Insulin
- Pfizer
- Therapeutic focus
- Marketed products
- R&D pipeline
- Exubera
- Novartis
- Therapeutic focus
- Marketed products
- R&D pipeline
- LAF237
- Merck KGaA
- Therapeutic focus
- Marketed products
- R&D pipeline
- Index
List of Figures
- Figure 1.1: Prevalence of obese and overweight adults in US, 1976-2000
- Figure 1.2: Proportion of type 2 diabetics diagnosed, 2003
- Figure 1.3: Management of type 2 diabetes by physician type, 2003
- Figure 1.4: Proportion of drug treated type 2 diabetics treated with insulin in monotherapy or combination, 2003
- Figure 2.5: Development timeline for antidiabetic drug classes, 1920-2004
- Figure 2.6: Overview of diagnosis rates, treatment rates and insulin prescribing trends in six major markets, 2003
- Figure 2.7: Approved combination therapies for type 2 diabetes, 2003
- Figure 2.8: Positive and negative developments influencing the antidiabetics market, 2004 & forwards
- Figure 2.9: Overview of the non-invasive insulin pipeline, 2004
- Figure 3.10: Insulin brands by company and type, 2004
- Figure 3.11: US/European market share of leading insulins (%), 1999-2003
- Figure 3.12: Humulin SWOT analysis
- Figure 3.13: NovoLin SWOT analysis
- Figure 3.14: Humalog SWOT analysis
- Figure 3.15: NovoLog SWOT analysis
- Figure 3.16: Apidra SWOT analysis
- Figure 3.17: Lantus SWOT analysis
- Figure 3.18: Levemir SWOT analysis
- Figure 4.19: Sales of OAD categories in Europe and US ($m), 2003
- Figure 4.20: Global market share of leading sulfonylureas (%), 1999-2003
- Figure 4.21: Amaryl SWOT analysis
- Figure 4.22: Glucotrol XL SWOT analysis
- Figure 4.23: Global market share of leading biguanides, 1999-2003
- Figure 4.24: Glucophage XR SWOT analysis
- Figure 4.25: Glucovance SWOT analysis
- Figure 4.26: US/European market share of leading TZDs (%), 1999-2003
- Figure 4.27: Actos SWOT analysis
- Figure 4.28: Avandia SWOT analysis
- Figure 4.29: Avandamet SWOT analysis
- Figure 4.30: US/European market share of leading AGIs (%), 1999-2003
- Figure 4.31: Precose/Glucobay SWOT analysis
- Figure 4.32: Basen SWOT analysis
- Figure 4.33: US/European market share of leading PGRs (%), 1999-2003
- Figure 4.34: Prandin/NovoNorm SWOT analysis
- Figure 4.35: Starlix SWOT analysis
- Figure 5.36: Eli Lilly s therapeutic focus, 2003-2010
- Figure 5.37: Novo Nordisk s therapeutic focus, 2003 and 2010
- Figure 5.38: Sanofi-Aventis therapeutic focus, 2003 & 2010
- Figure 5.39: Takeda s therapeutic focus, 2003 & 2010
- Figure 5.40: GSK s therapeutic focus, 2003 & 2010
- Figure 5.41: BMS s changing therapeutic focus, 2003-2010
- Figure 5.42: Pfizer s changing therapeutic focus, 2003-10
- Figure 5.43: Merck KGaA s changing therapeutic focus, 2003 & 2010
List of Tables
- Table 1.1: Prevalence of Type 2 diabetes (m), 2003-2012
- Table 1.2: US and European Sales by Drug Class ($m), 2002-2003
- Table 2.3: US/European sales category totals ($m), 2002-2003
- Table 3.4: US/European Sales of insulins by category ($m), 2002-2003
- Table 3.5: Insulin market share by company and territory (%), 2002-2003
- Table 3.6: Sales of leading insulins by country ($m), 2002-2003
- Table 3.7: Branded human insulins
- Table 3.8: Branded fast-acting human insulin analogs
- Table 3.9: Branded long-acting human insulin analogs
- Table 4.10: Frequency and level of dose of OADs
- Table 4.11: US/European OAD category market share (%), 2002-2003
- Table 4.12: US/European OAD Market Share by Company (%), 2002-2003
- Table 4.13: Sales of leading sulfonylureas by country ($m), 2002-2003
- Table 4.14: Branded sulfonylureas
- Table 4.15: Sales of leading biguanides by country ($m), 2002-2003
- Table 4.16: Branded biguanides
- Table 4.17: Proportion of patients receiving monotherapy versus combination therapy treatment (%), 2003
- Table 4.18: US/European sales of sulfonylurea + biguanide single-pills ($m), 1999-2003
- Table 4.19: Sales of leading TZDs by country ($m), 2002-2003
- Table 4.20: Branded TZDs
- Table 4.21: Sales of leading AGIs by country ($m), 2002-2003
- Table 4.22: Branded AGIs
- Table 4.23: Sales of leading PGRs by country (%), 2002-2003
- Table 4.24: Branded PGRs
- Table 5.25: US/European diabetes market share by company (%), 2002-2003
- Table 5.26: US Insulin Market Share by Company (%), 2002-2003
- Table 5.27: US/European sales of Eli Lilly s marketed diabetes portfolio ($m), 2002-2003
- Table 5.28: Projected sales of Eli Lilly s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.29: European insulin market share by company (%), 2002-2003
- Table 5.30: US/European sales of Novo Nordisk s marketed diabetes portfolio ($m), 2002-2003
- Table 5.31: Projected sales of Novo Nordisk s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.32: US/European sales of Sanofi-Aventis marketed diabetes portfolio ($m), 2002-2003
- Table 5.33: Projected sales of Sanofi-Aventis diabetes R&D pipeline ($m), 2003 & 2010
- Table 5.34: US/European sales of Takeda s marketed diabetes portfolio ($m), 2002-2003
- Table 5.35: Projected sales of Takeda s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.36: US/European sales of GSK s marketed diabetes portfolio, 2002-2003
- Table 5.37: GSK s diabetes R&D pipeline, 2003
- Table 5.38: US OAD Market Share by Company (%), 2002-2003
- Table 5.39: US/European sales of BMS s diabetes portfolio, 2002-2003
- Table 5.40: Projected sales of BMS s diabetes R&D pipeline ($m), 2007 & 2010
- Table 5.41: Projected sales of Merck KGaA s diabetes R&D pipeline ($m), 2007 & 2010
|
